While bankers and other Wall Street observers debate whether the initial public offering window really has opened for the industry, specialty pharma firm Horizon Pharma Inc. stepped up with its own filing for a proposed $86 million IPO. (BioWorld Today)

Genentech Inc. is turning again to Seattle Genetics Inc.'s antibody-drug conjugate platform, as the Bothell, Wash.-based biotech racks up additional licensing fees ahead of anticipated Phase III data and marketing submissions for lead internal lymphoma drug SGN-35. (BioWorld Today)

Shares of Genzyme Corp. continued climbing Thursday amid rumblings of a possible $70-per-share bid from Sanofi-Aventis SA, but whether $18.7 billion is a fair takeout price for the Cambridge, Mass.-based biotech clearly remains up for debate. (BioWorld Today)

Regeneron Pharmaceuticals Inc. expanded its nonexclusive deal with Astellas Pharma Inc. through 2023 in exchange for $165 million up front, bringing total committed funding stemming from licenses to its VelocImmune mouse antibody platform to roughly $2 billion. (BioWorld Today)

Five-year-old French biotech Cerenis Therapeutics SA pulled in its third major venture round, adding €40 million (US$51.9 million) in Series C funding to advance its lead program, HDL-mimetic CER-001, into Phase II testing in cardiovascular disease. (BioWorld International)